top | item 41937538

(no title)

benchtobedside | 1 year ago

TL;DR from the article: The study found that patients prescribed semaglutide had a significantly lower risk for Alzheimer’s disease than those who had taken one of the seven other diabetes drugs. The results were consistent across gender, age and weight.

The biggest difference was seen when comparing patients who took semaglutide to those who took insulin: Semaglutide patients had a 70% lower risk of Alzheimer’s, the study found.

Full link to the study itself: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz...

discuss

order

Someone1234|1 year ago

With the constant stream of positive news around GLP-1s, and ever-growing list of things they treat, we may all wind up on some dose with only the dose varying depending on what illness they're targeting.

nordsieck|1 year ago

> With the constant stream of positive news around GLP-1s, and ever-growing list of things they treat, we may all wind up on some dose with only the dose varying depending on what illness they're targeting.

So far, I haven't seen much evidence that GLP-1s have a positive effect on people who aren't overweight. And while I'll be the first to admit that the proportion of people who could benefit from these drugs is quite large, it's pretty far from everyone.

thefz|1 year ago

Why would taking a drug you don't need for the rest of your days be a good thing?

AStonesThrow|1 year ago

My PCP agrees that the great results I'm getting on Fen-Phen mean I won't need to switch!